ELM Advisors LLC purchased a new position in Agilent Technologies, Inc. (NYSE:A) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 3,409 shares of the medical research company’s stock, valued at approximately $202,000.
Several other hedge funds and other institutional investors have also modified their holdings of A. BlackRock Inc. raised its position in Agilent Technologies by 1,946.9% in the first quarter. BlackRock Inc. now owns 23,119,219 shares of the medical research company’s stock valued at $1,222,310,000 after buying an additional 21,989,739 shares during the period. FMR LLC raised its position in Agilent Technologies by 3.9% in the first quarter. FMR LLC now owns 21,588,407 shares of the medical research company’s stock valued at $1,141,379,000 after buying an additional 803,993 shares during the period. Vanguard Group Inc. raised its position in Agilent Technologies by 0.4% in the first quarter. Vanguard Group Inc. now owns 21,455,971 shares of the medical research company’s stock valued at $1,134,378,000 after buying an additional 75,886 shares during the period. State Street Corp raised its position in Agilent Technologies by 1.0% in the first quarter. State Street Corp now owns 14,457,425 shares of the medical research company’s stock valued at $764,348,000 after buying an additional 147,518 shares during the period. Finally, JPMorgan Chase & Co. raised its position in Agilent Technologies by 31.4% in the first quarter. JPMorgan Chase & Co. now owns 8,366,511 shares of the medical research company’s stock valued at $442,338,000 after buying an additional 1,999,376 shares during the period.
Shares of Agilent Technologies, Inc. (A) opened at 59.33 on Friday. The company has a market cap of $19.06 billion, a PE ratio of 33.35 and a beta of 1.30. The stock’s 50 day moving average price is $60.10 and its 200-day moving average price is $55.69. Agilent Technologies, Inc. has a 12-month low of $42.92 and a 12-month high of $61.84.
Agilent Technologies (NYSE:A) last announced its earnings results on Monday, May 22nd. The medical research company reported $0.58 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.48 by $0.10. Agilent Technologies had a net margin of 13.41% and a return on equity of 16.49%. The company had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same period in the prior year, the business earned $0.44 earnings per share. Agilent Technologies’s quarterly revenue was up 8.1% on a year-over-year basis. On average, equities research analysts forecast that Agilent Technologies, Inc. will post $2.23 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Wednesday, July 26th. Stockholders of record on Monday, July 3rd were given a dividend of $0.132 per share. The ex-dividend date of this dividend was Thursday, June 29th. This represents a $0.53 dividend on an annualized basis and a dividend yield of 0.89%. Agilent Technologies’s payout ratio is 29.78%.
ILLEGAL ACTIVITY WARNING: “ELM Advisors LLC Buys Shares of 3,409 Agilent Technologies, Inc. (NYSE:A)” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.com-unik.info/2017/08/12/elm-advisors-llc-invests-202000-in-agilent-technologies-inc-nysea-updated-updated-updated.html.
Several research firms have commented on A. BidaskClub lowered Agilent Technologies from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Jefferies Group LLC reissued a “buy” rating and issued a $66.00 price objective on shares of Agilent Technologies in a research report on Wednesday. Barclays PLC restated a “buy” rating and set a $67.00 target price on shares of Agilent Technologies in a research note on Wednesday, July 19th. Wells Fargo & Company upgraded Agilent Technologies from a “market perform” rating to an “outperform” rating and raised their target price for the company from $42.92 to $60.73 in a research note on Wednesday, July 12th. Finally, Morgan Stanley restated an “overweight” rating on shares of Agilent Technologies in a research note on Monday, July 10th. Two equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $60.12.
In related news, Director Paul N. Clark sold 3,866 shares of the stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $59.05, for a total value of $228,287.30. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director James Cullen sold 15,482 shares of the stock in a transaction that occurred on Wednesday, May 24th. The shares were sold at an average price of $59.04, for a total transaction of $914,057.28. The disclosure for this sale can be found here. Insiders have sold 112,608 shares of company stock worth $6,737,509 over the last quarter.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
What are top analysts saying about Agilent Technologies Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Agilent Technologies Inc. and related companies.